Vaccine Formulation/Presentation Guide

For further details please scroll down and click to see the Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) Emergency Use Authorization Fact Sheets or contact US Medical Information at PfizerMedicalInformation.com or 1-800-438-1985.

Emergency Use Authorization

Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and 12 years and older for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com.

Interchangeability (Primary Series for Individuals 12 Years of Age and Older)

When prepared according to their respective instructions for use, the FDA-approved COMIRNATY® and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, vaccine presentations should only be used for the ages specified on the vial labels, cartons, or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.
**Distinguishing Between Gray Cap Vials:** Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY® (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)\(^1\)

Verify the vials (including labels) prior to preparation and administration to help avoid dosing errors

<table>
<thead>
<tr>
<th>Name</th>
<th>PRIMARY SERIES</th>
<th>BOOSTER DOSE ONLY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Pfizer-BioNTech COVID-19 Vaccine</strong>&lt;br&gt;DO NOT DILUTE&lt;br&gt;NDC number: Multiple Dose Vial: 56267-0202-01</td>
<td><strong>Pfizer-BioNTech COVID-19 Vaccine, Bivalent</strong>&lt;br&gt;(Original and Omicron BA.4/BA.5)&lt;br&gt;DO NOT DILUTE&lt;br&gt;NDC number: Multiple Dose Vial: 56267-0304-01</td>
</tr>
<tr>
<td><strong>COMIRNATY</strong>&lt;br&gt;(COVID-19 Vaccine, mRNA)</td>
<td>DO NOT DILUTE&lt;br&gt;NDC number: Multiple Dose Vial: 0069-2025-01</td>
<td>|</td>
</tr>
<tr>
<td><strong>Variant Composition</strong></td>
<td><strong>Monovalent: 30 mcg modRNA-Original</strong>&lt;br&gt;(&quot;Monovalent&quot; refers to vaccine that encodes the spike protein of only the Original SARS-CoV-2)</td>
<td><strong>Bivalent: 15 mcg modRNA-Original and 15 mcg modRNA-Omicron BA.4/BA.5</strong></td>
</tr>
<tr>
<td><strong>Authorized Use (AU) or Indication</strong></td>
<td><strong>Primary Series AU:</strong>&lt;br&gt;as a 2-dose primary series to individuals 12 years of age and older; and a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise*&lt;br&gt;Primary Series Indication:&lt;br&gt;as a 2-dose primary series to individuals 12 years of age and older</td>
<td><strong>Bivalent AU:</strong>&lt;br&gt;for 12 years of age and older as a single booster dose administered at least 2 months after:&lt;br&gt;• completion of primary vaccination with any authorized or approved monovalent COVID-19 vaccine, or&lt;br&gt;• receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine</td>
</tr>
</tbody>
</table>

**Cap Color & Label**

- Gray caps and labels with gray borders

**Selected Safety Information**

Do not administer Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or Pfizer-BioNTech COVID-19 Vaccine, Bivalent to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of these vaccines.

**Management of Acute Allergic Reactions**

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Please see following page for dosage and storage information for individuals 12 years of age and older (purple and gray cap).

Please see full Important Safety Information and Indication & Authorized Use on pages 5 through 7.

Before administration, please scroll down and click or visit cvd vaccine-us.com to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.
Vaccine Formulation/Presentation Guide

Verify the vials (including labels) prior to preparation and administration to help avoid dosing errors

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Vial Cap Color</th>
<th>Dose</th>
<th>Dose Volume</th>
<th>Amount of Diluent Needed per Vial</th>
<th>Doses per Vial</th>
<th>Storage Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 years and older (See additional information in teal box to the right of table)</td>
<td>Gray</td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>NO DILUTION</td>
<td>Multiple dose vial: 6 doses per vial</td>
<td>Ultra-Low-Temperature (ULT) Freezer [-90 °C to -60 °C (-130 °F to -76 °F)] 12 months‡</td>
</tr>
<tr>
<td>12 years and older*</td>
<td>Gray</td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>NO DILUTION</td>
<td>6 doses per vial</td>
<td>Freezer [-25 °C to -15 °C (-13 °F to 5 °F)] DO NOT STORE 2 Weeks</td>
</tr>
<tr>
<td>12 years and older*</td>
<td>Purple</td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>1.8 mL†</td>
<td>6 doses per vial (after dilution)</td>
<td>Refrigerator [2 °C to 8 °C (35 °F to 46 °F)] 10 Weeks 1 month</td>
</tr>
</tbody>
</table>

*For vaccination of individuals advancing into the next age group (11 years of age turning 12 years of age) between any primary series dose, refer to the respective age-based Fact Sheet for Healthcare Providers for instructions for administration.

†ONLY use sterile 0.9% Sodium Chloride Injection, USP as the diluent. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

‡Regardless of storage condition, gray cap vaccine should not be used after 12 months from the date of manufacture printed on the vial and carton.

§Regardless of storage condition, purple cap vaccine should not be used past the 12-month expiry. For vials with expiry dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiry dates of June 2022 or beyond, the printed date on the label/carton reflects 9-month expiry.

Low dead-volume syringes and/or needles can be used to extract 6 doses from a single multiple dose vial. If standard syringes and needles are used, there may not be sufficient volume to extract 6 doses from a single vial.

Please see following page for dosage and storage information for individuals 6 months through 4 years of age and 5 through 11 years of age.

Please see full Important Safety Information and Indication & Authorized Use on pages 5 through 7.

Before administration, please scroll down and click or visit cvdvaccine-us.com to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.

Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized to prevent COVID-19 in individuals 6 months of age and older.

Identify the name on the vial label. Bivalent vial will specify: Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5).
For eligible individuals 6 months through 4 years of age and 5 through 11 years of age

For vaccination of individuals advancing into the next age group (4 years of age turning 5 years of age or 11 years of age turning 12 years of age) between any primary series dose, refer to the respective age-based Fact Sheet for Healthcare Providers for instructions for administration.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>PFIZER-BIONTECH COVID-19 VACCINE, DILUTE BEFORE USE‡</th>
<th>PFIZER-BIONTECH COVID-19 VACCINE, DILUTE BEFORE USE‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months through 4 years</td>
<td>Maroon</td>
<td>Orange</td>
</tr>
<tr>
<td>5 through 11 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&quot;Age 6m to &lt; 5y&quot; on vial label)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vial Cap Color</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maroon Orange Cap Vials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose 3 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose Volume 0.2 mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amount of Diluent Needed per Vial*</td>
<td>2.2 mL</td>
<td>1.3 mL</td>
</tr>
<tr>
<td>Doses per Vial 10 doses per vial (after dilution)</td>
<td>10 doses per vial (after dilution)</td>
<td></td>
</tr>
<tr>
<td>Storage Conditions</td>
<td>Storage Conditions</td>
<td>Storage Conditions</td>
</tr>
<tr>
<td>Ultra-Low-Temperature (ULT) Freezer [-90 °C to -60 °C (-130 °F to -76 °F)]</td>
<td>12 months†</td>
<td>12 months†</td>
</tr>
<tr>
<td>Freezer [-25 °C to -15 °C (-13 °F to 5 °F)]</td>
<td>DO NOT STORE</td>
<td>DO NOT STORE</td>
</tr>
<tr>
<td>Refrigerator [2 °C to 8 °C (35 °F to 46 °F)]</td>
<td>10 weeks</td>
<td>10 weeks</td>
</tr>
<tr>
<td>Room Temperature [8 °C to 25 °C (46 °F to 77 °F)]</td>
<td>12 hours prior to dilution (including any thaw time)</td>
<td>12 hours prior to dilution (including any thaw time)</td>
</tr>
<tr>
<td>After First Puncture [2 °C to 25 °C (35 °F to 77 °F)]</td>
<td>Discard after 12 hours‡</td>
<td>Discard after 12 hours‡</td>
</tr>
</tbody>
</table>

*ONLY use sterile 0.9% Sodium Chloride Injection, USP as the diluent. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.
†Regardless of storage condition, maroon and orange cap vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.
‡Vials should be discarded 12 hours after dilution, even though some vial and carton labels may state that a vial should be discarded 6 hours after dilution. The information in the Fact Sheet supersedes the information printed on vial labels and cartons.

The vial labels may state “Age 2y to < 5y” or “Age 6m to < 5y” and carton labels may state “For age 2 years to < 5 years” or “For age 6 months to < 5 years.” Vials with either printed age range can be used for individuals 6 months through 4 years of age.

Please see full Important Safety Information and Indication & Authorized Use on pages 5 through 7. Before administration, please scroll down and click or visit cvdvaccine-us.com to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.
Important Safety Information and Indication & Authorized Use

Important Safety Information
Do not administer Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or Pfizer-BioNTech COVID-19 Vaccine, Bivalent to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of these vaccines.

Management of Acute Allergic Reactions
Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis
Myocarditis and pericarditis have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Postmarketing safety data with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

Postmarketing data with authorized or approved monovalent mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following receipt of the second primary series dose or first booster dose, with most booster doses likely administered at least 5 months after completing primary vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncopal Events
Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Limitation of Effectiveness
Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent may not protect all vaccine recipients.

Adverse Reactions
Primary Series Adverse Events:
Pfizer-BioNTech COVID-19 Vaccine
In a clinical study (3 mcg modRNA) in participants 6 through 23 months of age, adverse reactions following administration of any dose included irritability (68.4%), decreased appetite (38.6%), tenderness at the injection site (26.4%), injection site redness (17.8%), fever (14.4%), injection site swelling (7.3%), and lymphadenopathy (0.2%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY
In clinical studies (30 mcg modRNA) of adolescents 12 through 15 years of age, the most commonly reported adverse reactions (≥8%) were pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), and injection site redness (8.6%).

In clinical studies (30 mcg modRNA) of participants 16 through 55 years of age, the most commonly reported adverse reactions (≥10%) were pain at the injection site (88.6%), fatigue (70.1%), headache (64.9%), muscle pain (45.5%), chills (41.5%), joint pain (27.5%), fever (17.8%), and injection site swelling (10.6%).

Please see additional Important Safety Information and Indication & Authorized Use on pages 6 and 7.
Before administration, please scroll down and click or visit cvdvaccine-us.com to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.
In clinical studies (30 mcg modRNA) of participants 56 years of age and older, the most commonly reported adverse reactions (≥10%) were pain at the injection site (78.2%), fatigue (56.9%), headache (45.9%), muscle pain (32.5%), chills (24.8%), joint pain (21.5%), injection site swelling (11.8%), fever (11.5%), and injection site redness (10.4%).

**Booster Dose Adverse Events:**

**Pfizer-BioNTech COVID-19 Vaccine**

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of a single booster dose were injection site pain (73.9%), fatigue (45.6%), headache (34.0%), muscle pain (18.3%), injection site swelling (16.4%), injection site redness (15.6%), chills (10.5%), fever (6.7%), joint pain (6.7%), diarrhea (4.9%), lymphadenopathy (2.5%), and vomiting (2.4%).

**Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY**

In a clinical study (30 mcg modRNA) of participants 18 through 55 years of age, adverse reactions following administration of a first booster dose were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%).

**Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)**

The safety of a booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent is based on:

- safety data from a clinical study which evaluated a booster dose of Pfizer-BioNTech’s bivalent COVID-19 vaccine (Original and Omicron BA.1), not authorized or approved, hereafter referred to as bivalent vaccine (Original and Omicron BA.1),
- safety data from clinical trials which evaluated primary and booster vaccination with Pfizer-BioNTech COVID-19 Vaccine, and
- post marketing safety data with Pfizer-BioNTech COVID-19 Vaccine.

The safety data accrued with the bivalent vaccine (Original and Omicron BA.1) and with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

The clinical study that evaluated a booster dose of the bivalent vaccine (Original and Omicron BA.1) included participants 55 years of age and older. Adverse reactions following administration of the bivalent vaccine (Original and Omicron BA.1) as a second booster dose included pain at the injection site (58.1%), fatigue (49.2%), headache (33.6%), muscle pain (22.3%), chills (13.0%), joint pain (11.3%), injection site redness (7.0%), injection site swelling (6.6%), fever (5.0%), lymphadenopathy (0.3%), nausea (0.3%), and malaise (0.3%).

In a clinical study of participants 18 through 55 years of age, adverse reactions following administration of a first booster dose of Pfizer-BioNTech COVID-19 Vaccine were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%).

**Post Authorization Experience**

Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (eg, rash, pruritus, urticaria, angioedema), diarrhea, vomiting, pain in extremity (arm), and syncope have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Myocarditis and pericarditis have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of Pfizer-BioNTech COVID-19 Vaccine and post authorization use of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

**COMIRNATY**

**Indication & Authorized Use**

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. It is also authorized for emergency use to provide a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.

**Pfizer-BioNTech COVID-19 Vaccine**

**Authorized Use**

Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
Interchangeability (Primary Series for Individuals 12 Years of Age and Older)

When prepared according to their respective instructions for use, the FDA-approved COMIRNATY and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, vaccine presentations should only be used for the ages specified on the vial labels, cartons, or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Authorized Use


Before administration of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), please click to see

- EUA Fact Sheet for Vaccination Providers (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap
- EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Booster Dose 12 years of age and older), DO NOT DILUTE, Gray Cap
- EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Primary Series and Bivalent Booster Dose 12 years of age and older)

Before administration of Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY (COVID-19 Vaccine, mRNA), please click to see

- Full Prescribing Information (Primary Series 12 years of age and older), DO NOT DILUTE, Gray Cap
- Full Prescribing Information (Primary Series 12 years of age and older), DILUTE BEFORE USE, Purple Cap
- EUA Fact Sheet for Vaccination Providers (Primary Series 12 years of age and older), DO NOT DILUTE, Gray Cap
- EUA Fact Sheet for Vaccination Providers (Primary Series 12 years of age and older), DILUTE BEFORE USE, Purple Cap
- EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Booster Dose 12 years of age and older)
- EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Primary Series and Bivalent Booster Dose 12 years of age and older)

Before administration of Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Find additional resources about the vaccine at www.cvdvaccine-us.com

© 2022 Pfizer Inc. All rights reserved. September 2022